Anil Koul
Vice President, Global Public Health,
Johnson & Johnson
Anil Koul, PhD is the Vice President of Global Public Health at Johnson & Johnson, with over 25 years of experience in drug discovery. He is renowned for co-developing Bedaquiline, a groundbreaking treatment for drug-resistant tuberculosis, used by over a million patients worldwide. Dr. Koul has also advanced several other drug candidates, including Rilematovir for RSV.
He holds a PhD from the Max Planck Institute and serves as a Professor of Translational Drug Discovery at the London School of Hygiene & Tropical Medicine. With over 35 patents and numerous publications, Dr. Koul is a leader in global health innovation and a passionate mentor to the next generation of scientists.